- There are Currently A Few Tests, Including Blood Tests, That Can Be USed To Help Diagnose Alzheimer’s and Determine Which Stage The Disease is in.
- Researchers at Washu Medicine have revealed Blood Test that can not only Help Diagnose Alzheimer’s Disease, but also provides information to doctors on how far the desire you have progressed.
- This Builds on Previous Research on a New Protein Biomarker for Tau Tangles in Alzheimer’s Disease.
Researchers Estimate That More than
There are currently to few tests that can be used to help diagnose Alzheimer’s Disease, Such as Blood Tests Looking for The Proteins
However, People Are Not Always Diagnosed at the Beginning of the Disease – They Can Be Diagnosed at Different Stages, Which Can Influence How they are treated.
Now, Researchers at Washu Medicine in St. Louis, Mo, have revealed Blood Test that can not only Help Diagnose Alzheimer’s Disease But Also Provide Insight to Doctors On How Far The Disease Has Progreso, Helping Them Determine The Right Treatment Path.
A Study On This New Blood Was Recently Published in the Journal
New Protein Biomarker for Tau Tangles
For This New Blood Test, Focused on A Protein Called Mtbr-Tau243, Which Researchers of This Study identified a potential
“Mtbr-tau243 is a chipped (off) piece of the protein in alzheimer’s tau tangles,” Randall J. Bateman, MD, The Charles F. and Joanne Knight Distinguished Profe Medical News Today. “The Blood Test Measures This Piece of Tau Tangles in the Blood As a Measure of How Many Tangles are in the brain.”
“New Biomarkers Are Tools that allow US to Track The Disease in Different Ways,” Bateman Continued. “Just Like Doctors Use Stethoscope, X-Ray, and cat scan to Measure Different Aspects of the Disease, these biomarkers enables to measure difference aspects of Alzheimer’s Disease. By tracking different process of Alzheimer’s Disera New and Better Treatments for Alzheimer’s Disease. ”
“The New Biomarker-Emtbr-Tau243 Plasma-Reflects Changes in Tau Pathology Occurring in the Clinical Symptomatic Phase of Alzheimer’s Disease and Can Be used to Stage Alzheimer’s Disease Tauopathy, and to determine if cognitive symptoms are Likely Alzheimer’s Disease Tau Pathology, ”Added Kanta Horie, PHD, Voluntary Research Associate Professor of Neurology at Washu Medicine in St. Louis, Mo, and Both Co-Fircst and Co-Cor Answer Author of This Study.
“Also, many Therapeutic Developments are ongoing including anti -myloid and anti-tau. For Alzheimer’s Disease. “
Biomarker Up To 200 Times Higher in Late-Stage Alzheimer’s
During the Study, Refrachers Tested Study Participants from Three Main Stages of Alzheimer’s Disease: Presymptomatic, Early-Stage With
The Scientists Found that Blood Mtbr-tau243 Levels reflect the amount of tau tangles in the brain with 92% Accuracy.
Among Participants Showing Cognitive Symptoms of Alzheimer’s Disease, Recovered Whig Mtbr-Tau243 Levels were significantly Higher for Participants at the Mile Cognitive Stage, and Up to 200 Times Higher for Thue in The Late Symptomatic Disease Stage.
A New Protein Biomarker for Alzheimer’s
“The cognitive decline in Alzheimer’s Disease Is Highly Associated with (Tau) neurofibrillary tangles (NFTS) Pathology in (The) brain, not Amyloid Pathology Platques. For US to the Drastic Increase of Mtbr-tau243 in the Dementia Stage Combase to the preclinical Alzheimer’s Disease Stage, which suggests the validation to Characterize the plasma mtbr-tau243 biomarker as the tau nfts-specific biomarker.
– Kanta Horie, PhD
“The meaning of finding increasesing amount of mtbr-243 Related to Alzheimer’s Symptoms-Memory Loss and Thinking Impairment-is (that) This Discovery Now Allows to Track The Clinical Symptoms of Alzheimer’s Disease with A Blood Test,” Bateman Explained.
Blood Tests: Next Step In Alzheimer’s Diagnosis and Treatment
“This New Blood Test Confirm The Amount of Tau Tangles In The Brain That Helps Determine The Stage of Alzheimer’s Disease and if cognitive decline is Likely Due to Alzheimer’s Disease. Alzheimer’s Disease. “
– Randall J. Bateman, MD
MNT Spoke with Manisha Parulekar, MD, FACP, AGSF, CMD, Director of the Division of Geriatrics at Hackensack University Medical Center and Co-Director of the Center for Memory Loss and Brain Health at Hackensack University Medical Center in New Jersey, About This Study.
Parulekar Commeable that This Blood Test Represents A Logical Next Step In Alzheimer’s Diagnosis and Treatment, Building Upon Previous Research and Addressing Significant Unmet Needs.
“Scientists have identified Key Biomarkers Associated with Alzheimer’s, Such as Amyloid-Beta Planks and Tau Tangles in the Brain,” She explained. “Earlier Diagnostic Methods, Like Pet Scans and brain Fluid Analysis, Could Detet before Biomarkers, But They Are Expensive, Invasive, and Not Readily Accessible.”
“A Blood Test Offers A Much Simpler and Less Costly Alternative. There’s a Growing Understanding That Early Diagnosis of Alzheimer’s, which is a complex process, is crucial is Crucial for Effective Intervention. Current Treatments, While Limited, May Be More beneficial in The Early Stages of the Disease. Readily Available Blood Test Could Enable Much Earlier Detection Than Current Methods, Allowing for Earlier Intervention and Potentially Slowing Disease Progression. “
– Manisha Parulekar, MD, FACP, AGSF, CMD
“The Initial Study Needs to Be Replicated in Larger and More Diverse Populans to Confirm ITS Accuracy and Reliability Across Different Demographics, Ethnicities, and Stages of the Disease,” Parulekar Added. “This includes individuals with other neurological conditions to enseure specificity. Clear and Standardized Protocols for Blood Collection, Processing, and Analysis Must Be establish to reure consisting and reproducible results ROSS Different Laboratories and Healthcare Settings.”
